Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genetic Testing, But No Drugs, On Revised List Of Potential Medicare NCD Topics

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS includes genetic testing on its updated list of potential topics for Medicare national coverage determinations, released Nov. 27. But no biopharmaceuticals are on the list this time around.

You may also be interested in...



CMS Will Weigh Three New Tech Assessments On Genetic Testing For Cancer

Two of the assessments are intended to inform an upcoming Medicare Evidence Development and Coverage Advisory Committee meeting.

CMS Proposal To Expand Aprepitant Coverage Could Also Benefit Tesaro’s Rolapitant

CMS’ proposed update to its Medicare Part B National Coverage Determination would provide payment for aprepitant when used for patients receiving moderately emetogenic chemotherapy, not just highly emetogenic treatments.

Medicare Part B: Commentary By CMS Officials

CMS officials Jonathan Blum, Louis Jacques and Tamara Jensen addressed a number of Medicare Part B-related topics of interest to the biopharmaceutical industry at the FDA/CMS Summit, including reimbursement for high-priced oncology drugs, coverage with evidence development and national coverage determinations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel